- In November 2024, Santen Pharmaceutical Co., Ltd. announced that it had entered into a commercial collaboration agreement with Arctic Vision for ARVN001, a triamcinolone acetonide suprachoroidal injectable suspension, along with its injector featuring the patented SCS Microinjector technology. This partnership is focused on the treatment of uveitic macular edema (UME) and other ophthalmic indications under development, specifically for China, excluding Taiwan, Hong Kong, and Macau (hereinafter referred to as the Territory).
- In April 2024, Roivant and Priovant Therapeutics announced positive results from the Phase 2 NEPTUNE study (NCT05523765) evaluating brepocitinib for the treatment of non-anterior non-infectious uveitis (NIU). The study found that at week 24, 29% (5/17) of participants in the brepocitinib 45 mg group and 44% (4/9) in the 15 mg group met the treatment failure criteria, with the lower failure rates indicating a greater benefit from the treatment.
- In March 2024, Kiora Pharmaceuticals, Inc. announced the publication of results from a Phase 1 double-masked study of KIO-101, a powerful non-steroidal anti-inflammatory agent. KIO-101 contains the same active molecule as KIO-104, which is part of a class of potent anti-inflammatory agents. The study demonstrated that a 12-day topical treatment of KIO-101, administered at multiple doses, was well tolerated by both healthy volunteers and patients with eye inflammation.
- In January 2024, Tarsier Pharma, Ltd. announced that it had received approval from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and the proposed statistical analysis of the Tarsier-04 Phase 3 trial. This trial is designed to evaluate the efficacy of TRS01 eye drops for treating non-infectious uveitis, including uveitic glaucoma.
- In October 2021, Bausch + Lomb and Clearside Biomedical, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in treating macular edema associated with uveitis, a type of eye inflammation. With this FDA approval, XIPERE becomes the first and only treatment in the U.S. to utilize the suprachoroidal space for addressing macular edema in uveitis patients.
Frequently Asked Questions
Companies such as Alcon Inc. (Switzerland), AbbVie Inc. (U.S.), Bayer AG (Germany), Bausch + Lomb (Canada) and Gilead Sciences, Inc. (U.S.) are the major companies in the anterior uveitis treatment market.
In January 2024, Tarsier Pharma, Ltd. received approval from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and the proposed statistical analysis of the Tarsier-04 Phase 3 trial. In October 2021, Bausch + Lomb and Clearside Biomedical, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in treating macular edema associated with uveitis.
The countries covered in the anterior uveitis treatment market are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
